PMID- 30374624
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 98
IP  - 2
DP  - 2019 Feb
TI  - Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine 
      receptor 2 in diffuse large B cell lymphoma.
PG  - 413-422
LID - 10.1007/s00277-018-3522-3 [doi]
AB  - Aberrant monocyte chemoattractant protein-1 (MCP-1) and CC chemokine receptor 2 
      (CCR2) expression in malignant tissues have been reported; however, their role in 
      hematological malignancies prognosis remains little known. The aim of this study 
      was to investigate the prognostic value of MCP-1 and CCR2 expression in patients 
      with diffuse large B cell lymphoma (DLBCL). The study included 221 patients with 
      DLBCL. MCP-1 and CCR2 expression was analyzed by immunohistochemical staining and 
      its correlations with clinicopathologic features and prognosis were evaluated. 
      High expression of MCP-1 or CCR2 was correlated with clinicopathological 
      characteristics, and an adverse prognostic factor for overall survival (OS) and 
      progression-free survival (PFS) of DLBCL patients. Also, significant positive 
      correlation between MCP-1 and CCR2 expression was revealed (r = 0.545, 
      P < 0.001). Patients with high MCP-1 or high CCR2 expression had significantly 
      poorer OS and PFS than those with low MCP-1 or low CCR2 expression (OS: 
      P < 0.001, P < 0.001; PFS: P < 0.001, P < 0.001), respectively, even in the 
      rituximab era, and MCP-1 or CCR2 expression could further identify high-risk 
      patients otherwise classified as low/intermediate risk by the International 
      Prognostic Index (IPI) alone. Furthermore, incorporation of MCP-1 or CCR2 
      expression into the IPI score could improve prognostic value for OS. This is the 
      first report describing the clinicopathological features and survival outcome 
      according to expression of MCP-1 and CCR2 in DLBCL.
FAU - Li, Yan-Li
AU  - Li YL
AD  - Department of Pathology, Anhui Medical University, Hefei, Anhui, 230032, People's 
      Republic of China.
AD  - Department of Pathology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230022, People's Republic of China.
FAU - Shi, Zhi-Hu
AU  - Shi ZH
AD  - Department of Pathology, Anhui Ji Min Cancer Hospital, Hefei, Anhui, 230012, 
      People's Republic of China.
FAU - Wang, Xian
AU  - Wang X
AD  - Department of Pathology, Anhui Medical University, Hefei, Anhui, 230032, People's 
      Republic of China.
AD  - Department of Pathology, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230601, People's Republic of China.
FAU - Gu, Kang-Sheng
AU  - Gu KS
AD  - Department of Oncology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230022, People's Republic of China.
FAU - Zhai, Zhi-Min
AU  - Zhai ZM
AD  - Department of Hematology, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230601, People's Republic of China. zzzm889@163.com.
LA  - eng
GR  - 81700194/National Natural Science Foundation of China/
GR  - XJ201511/Scientific Research of BSKY from Anhui Medical University/
GR  - KJ2016A328/University Natural Science Research Project of Anhui Province/
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20181029
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chemokine CCL2/*blood
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Lymphoma, Large B-Cell, Diffuse/blood/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*blood
MH  - Receptors, CCR2/*blood
MH  - Survival Rate
OTO - NOTNLM
OT  - CC chemokine receptor 2
OT  - Diffuse large B cell lymphoma
OT  - Monocyte chemoattractant protein-1
OT  - Overall survival
OT  - Prognostic value
OT  - Progression-free survival
EDAT- 2018/10/31 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/10/31 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2018/10/09 00:00 [accepted]
PHST- 2018/10/31 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/10/31 06:00 [entrez]
AID - 10.1007/s00277-018-3522-3 [pii]
AID - 10.1007/s00277-018-3522-3 [doi]
PST - ppublish
SO  - Ann Hematol. 2019 Feb;98(2):413-422. doi: 10.1007/s00277-018-3522-3. Epub 2018 
      Oct 29.